1.Mutations in the D-loop region of mitochondrial DNA in ovarian tumors.
Hong-hui SHI ; Liu VINCENT ; Ngan HEXTAN ; Xiu-yu YANG
Acta Academiae Medicinae Sinicae 2002;24(2):170-173
OBJECTIVETo investigate mutations in the D-loop region of mitochondrial DNA in ovarian tumors.
METHODSThe D-loop region of 25 epithelial ovarian tumors together with the adjacent normal tissues were amplified by PCR and sequenced.
RESULTSAmong the 25 ovarian tumors, 26 mutations were identified with the mutation rate of 32%. 19 mutations were detected in two cases of borderline carcinoma which was a special type of epithelial ovarian carcinoma. There were 6 microsatellite instabilities among the mutations and 11 new polymorphisms which were not reported previously in the GenBank.
CONCLUSIONSThe D-loop region of mitochondrial DNA is a highly polymorphoric and mutable region and the mutation rate is relatively high in patients with ovarian tumors.
Cystadenocarcinoma, Serous ; genetics ; DNA, Mitochondrial ; genetics ; Female ; Humans ; Ovarian Neoplasms ; genetics ; Point Mutation ; Polymorphism, Genetic
4.Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors.
Aijun LIU ; Lezhen CHEN ; Hextan Y S NGAN ; U S KHOO ; Yun ZHAO ; Annie N Y CHEUNG
Chinese Medical Sciences Journal 2002;17(2):106-111
OBJECTIVETo determine the apoptotic and proliferative activities in various ovarian epithelial tumors.
METHODSFormalin-fixed, paraffin-embedded tissues of 86 ovarian epithelial tumors, including 52 adenocarcinomas, 23 borderline tumors and 11 cystadenoma, were retrieved. Apoptotic (AI) and proliferative (PI) index were estimated using the monoclonal antibodies: M30, Ki-67 and Ki-S1 in these tumors. Quantitative assessment of AI and PI was estimated by calculating the percentage of positive cells among no less than 1000 tumor cells.
RESULTSStatistically significant difference in AI was found between benign and borderline tumors or carcinomas (P = 0.028, 0.001, respectively). Significant differences in PI, as assessed by both Ki-67 and topo IIalpha, were demonstrated between carcinomas and benign or borderline tumors (both P < 0.001). Benign tumors had both low PI and AI; borderline tumors had lower PI but higher AI, while adenocarcinomas had both high proliferative and high apoptotic rates. Among borderline tumors, serious tumors had significantly lower AI and higher PI than mucinous ones.
CONCLUSIONThe results suggest that apoptotic and proliferative activities play important roles in the pathogenesis and development of ovarian borderline and malignant tumors. The high apoptotic rate in borderline tumor may explain its relatively indolent behavior while the high proliferative rate in carcinomas tends to explain its aggressive behavior.
Antigens, Neoplasm ; Apoptosis ; Carcinoma, Endometrioid ; chemistry ; pathology ; Cell Division ; Cystadenocarcinoma, Serous ; chemistry ; pathology ; Cystadenoma, Mucinous ; chemistry ; pathology ; Cystadenoma, Serous ; chemistry ; pathology ; DNA Topoisomerases, Type II ; analysis ; DNA-Binding Proteins ; Female ; Humans ; Ki-67 Antigen ; analysis ; Ovarian Neoplasms ; chemistry ; pathology
5.Association between High Diffusion-Weighted Imaging-Derived Functional Tumor Burden of Peritoneal Carcinomatosis and Overall Survival in Patients with Advanced Ovarian Carcinoma
He AN ; Jose AU PERUCHO ; Keith WH CHIU ; Edward S HUI ; Mandy MY CHU ; Siew Fei NGU ; Hextan YS NGAN ; Elaine YP LEE
Korean Journal of Radiology 2022;23(5):539-547
Objective:
To investigate the association between functional tumor burden of peritoneal carcinomatosis (PC) derived from diffusion-weighted imaging (DWI) and overall survival in patients with advanced ovarian carcinoma (OC).
Materials and Methods:
This prospective study was approved by the local research ethics committee, and informed consent was obtained. Fifty patients (mean age ± standard deviation, 57 ± 12 years) with stage III–IV OC scheduled for primary or interval debulking surgery (IDS) were recruited between June 2016 and December 2021. DWI (b values: 0, 400, and 800 s/mm2 ) was acquired with a 16-channel phased-array torso coil. The functional PC burden on DWI was derived based on K-means clustering to discard fat, air, and normal tissue. A score similar to the surgical peritoneal cancer index was assigned to each abdominopelvic region, with additional scores assigned to the involvement of critical sites, denoted as the functional peritoneal cancer index (fPCI). The apparent diffusion coefficient (ADC) of the largest lesion was calculated. Patients were dichotomized by immediate surgical outcome into high- and low-risk groups (with and without residual disease, respectively) with subsequent survival analysis using the Kaplan-Meier curve and log-rank test. Multivariable Cox proportional hazards regression was used to evaluate the association between DWI-derived results and overall survival.
Results:
Fifteen (30.0%) patients underwent primary debulking surgery, and 35 (70.0%) patients received neoadjuvant chemotherapy followed by IDS. Complete tumor debulking was achieved in 32 patients. Patients with residual disease after debulking surgery had reduced overall survival (p = 0.043). The fPCI/ADC was negatively associated with overall survival when accounted for clinicopathological information with a hazard ratio of 1.254 for high fPCI/ADC (95% confidence interval, 1.007–1.560; p = 0.043).
Conclusion
A high DWI-derived functional tumor burden was associated with decreased overall survival in patients with advanced OC.
6.A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
Ting DENG ; Kaijiang LIU ; Liang CHEN ; Xiaojun CHEN ; Hua Wen LI ; Hongyan GUO ; Huijiao ZHANG ; Libing XIANG ; Xin FENG ; Xiaoyu WANG ; Hextan YS NGAN ; Jianguo ZHAO ; Dongling ZOU ; Qing LIU ; Jihong LIU
Journal of Gynecologic Oncology 2023;34(3):e52-
Background:
The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).
Methods
We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB EOC and fallopian tube carcinomas (FTC). The hypothesis is that the oncological outcomes provided by comprehensive staging surgery without lymphadenectomy are non-inferior to those of conventional completion staging surgery in early-stage EOC and FTC patients who have indications for post-operative adjuvant chemotherapy. Patients assigned to experimental group will undergo comprehensive staging surgery, but lymphadenectomy. Patients assigned to comparative group will undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy. All subjects will receive 3–6 cycles of standard adjuvant chemotherapy. Major inclusion criteria are pathologic confirmed stage IA-IIB EOC or FTC, and patients have indications for adjuvant chemotherapy either confirmed by intraoperative fast frozen section or previous pathology after an incomplete staging surgery. Major exclusion criteria are non-epithelial tumors and low-grade serous carcinoma. Patients with severe rectum involvement which lead to partial rectum resection will be excluded. The sample size is 656 subjects. Primary endpoint is disease-free survival.
7.Asian society of gynecologic oncology workshop 2010.
Dong Hoon SUH ; Jae Weon KIM ; Mohamad Farid AZIZ ; Uma K DEVI ; Hextan Y S NGAN ; Joo Hyun NAM ; Seung Cheol KIM ; Tomoyasu KATO ; Hee Sug RYU ; Shingo FUJII ; Yoon Soon LEE ; Jong Hyeok KIM ; Tae Joong KIM ; Young Tae KIM ; Kung Liahng WANG ; Taek Sang LEE ; Kimio USHIJIMA ; Sang Goo SHIN ; Yin Nin CHIA ; Sarikapan WILAILAK ; Sang Yoon PARK ; Hidetaka KATABUCHI ; Toshiharu KAMURA ; Soon Beom KANG
Journal of Gynecologic Oncology 2010;21(3):137-150
This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to enhance the communication among Asian countries prior to the 2nd biennial meeting of Australian Society of Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview, fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally, chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy in ovarian cancer were presented.
Asia
;
Asian Continental Ancestry Group
;
Chemoradiotherapy
;
Endometrial Neoplasms
;
Female
;
Fertility
;
Humans
;
Hysterectomy
;
Laparoscopy
;
Lymph Node Excision
;
Mass Screening
;
Ovarian Neoplasms
;
Uterine Cervical Neoplasms
;
Vaccination
8.Asian Society of Gynecologic Oncology International Workshop 2014.
Jeong Yeol PARK ; Hextan Yuen Sheung NGAN ; Won PARK ; Zeyi CAO ; Xiaohua WU ; Woong JU ; Hyun Hoon CHUNG ; Suk Joon CHANG ; Sang Yoon PARK ; Sang Young RYU ; Jae Hoon KIM ; Chi Heum CHO ; Keun Ho LEE ; Jeong Won LEE ; Suresh KUMARASAMY ; Jae Weon KIM ; Sarikapan WILAILAK ; Byoung Gie KIM ; Dae Yeon KIM ; Ikuo KONISHI ; Jae Kwan LEE ; Kung Liahng WANG ; Joo Hyun NAM
Journal of Gynecologic Oncology 2015;26(1):68-74
The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.
Female
;
Fertility Preservation/methods
;
Genital Neoplasms, Female/*therapy
;
Humans
;
Ovarian Neoplasms/therapy
;
Translational Medical Research/methods
;
Uterine Cervical Neoplasms/therapy